Skip to search formSkip to main contentSkip to account menu

MVAp53 vaccine

Known as: Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVA-p53, MVA-p53 Vaccine 
A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cancer Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have… 
Review
2014
Review
2014
Antiviral Perspectives for Chikungunya Virus
Chikungunya virus (CHIKV) is a mosquito-borne pathogen that has a major health impact in humans and causes acute febrile illness… 
Highly Cited
2012
Highly Cited
2012
Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
A single vaccination with MVA-NP+M1 boosts T-cell responses to conserved influenza antigens in humans. Protection against… 
Highly Cited
2012
Highly Cited
2012
A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years
Background Current influenza vaccines have reduced immunogenicity and are of uncertain efficacy in older adults. We assessed the… 
Highly Cited
2011
Highly Cited
2011
The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens
ABSTRACT Attenuated poxvirus vectors expressing human immunodeficiency virus type 1 (HIV-1) antigens are considered promising HIV… 
Highly Cited
2003
Highly Cited
2003
Immunization of Newborn Rhesus Macaques with Simian Immunodeficiency Virus (SIV) Vaccines Prolongs Survival after Oral Challenge with Virulent SIVmac251
ABSTRACT There is an urgent need for active immunization strategies that, if administered shortly after birth, could protect… 
Highly Cited
2001
Highly Cited
2001
Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.
Highly Cited
2000
Highly Cited
2000
Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV
ABSTRACT Prior studies demonstrated that immunization of macaques with simian immunodeficiency virus (SIV) Gag-Pol and Env… 
Highly Cited
1997
Highly Cited
1997
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Highly Cited
1995
Highly Cited
1995
Non‐replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)